PubmedID,Title,Publication Date,Non-academic Author(s),Company Affiliation(s),Corresponding Author Email
29364287,The biology and management of non-small cell lung cancer.,2018-01-24,Boshoff Chris,Pfizer,None
34385702,Toward personalized treatment approaches for non-small-cell lung cancer.,2021-08-01,Boshoff Chris,Pfizer,roy.herbst@yale.edu.
35420921,Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer.,2022-05-20,Yamada Shunsuke; Haas Gabriel P,Astellas Pharma,None
37996402,Evaluation of circulating plasma proteins in breast cancer using Mendelian randomisation.,2023-11-24,Huang Tzu-Hsuan,Pfizer,anders.malarstig@ki.se.
38320501,Enzalutamide and Quality of Life in Biochemically Recurrent Prostate Cancer.,2023-12-01,Ganguli Arijit,Astellas,None
36749874,CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2- Metastatic Breast Cancer.,2023-04-14,Muñoz-Mateu Montserrat,Translational Genomics and Targeted,None
38383216,Histone lysine acetyltransferase inhibitors: an emerging class of drugs for cancer therapy.,2024-03-01,White Jeffrey; Derheimer Frederick A; Jensen-Pergakes Kristen; O'Connell Shawn; Sharma Shikhar; Spiegel Noah; Paul Thomas A,Pfizer,thomas.a.paul@pfizer.com.
33257855,The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1 mutant lung cancer.,2020-12-01,Wang Hui; Unsal-Kacmaz Keziban,Pfizer; Cancer,jiyeonk@uic.edu.
36692420,Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer.,2023-03-01,Zhang Yi; Tacheva-Grigorova Silvia K; Sutton Janette; Melton Zea; Mak Yvonne S L; Lay Cecilia; Smith Bryan A; Van Blarcom Thomas; Sasu Barbra J; Panowski Siler H,Allogene,None
37643677,Error-corrected next generation sequencing - Promises and challenges for genotoxicity and cancer risk assessment.,2023-01-01,Kidd Darren; Salk Jesse J; Zhang Shaofei,TwinStrand Biosciences; Pfizer,cchen@hesiglobal.org.
37146438,Effectiveness and safety of anticoagulants among venous thromboembolism cancer patients with and without brain cancer.,2023-06-01,Noxon Virginia; Bruette Robert; Shah Shrushti; Hines Dionne M; Alfred Tamuno; Luo Xuemei,STATinMED; Pfizer,alexander.cohen@kcl.ac.uk.
36625843,Challenges to Using Big Data in Cancer.,2023-04-14,Davis Gerard J; Gawel Susan H; Kirsch Ilan R; Shi George,Adaptive,None
37927299,Management of breast cancer patients with <i>BRCA</i> gene mutations in Jordan: perspectives and challenges.,2023-10-01,Debs Jamil; Al Masri Sarah,Pfizer,None
32732669,"Price, Cost, and Value of Cancer Medicines: A Pharmaceutical Industry Perspective.",2020-01-01,Rothenberg Mace L,From Pfizer,None
30217855,Kidney cancer: The next decade.,2018-10-01,Boshoff Chris,Pfizer,chris.boshoff@pfizer.com.
39177933,Trends in HR+ metastatic breast cancer survival before and after CDK4/6 inhibitor introduction in the United States: a SEER registry analysis of patients with HER2- and HER2+ metastatic breast cancer.,2024-11-01,Stergiopoulos Stella; Cha-Silva Ashley S; Makari Doris,Pfizer,brufskyam@upmc.edu.
34176404,The evolution of cyclin dependent kinase inhibitors in the treatment of cancer.,2021-10-01,Dann Stephen; Liu Feng; Wong Gilbert Y; Krupka Heike,Pfizer,None
31871299,Progress and Opportunities to Advance Clinical Cancer Therapeutics Using Tumor Dynamic Models.,2020-04-15,Bottino Dean; de Alwis Dinesh P,Millennium,rene.bruno@roche.com.
39377971,Physical activity before and after cancer diagnosis and mortality risk in three large prospective cohorts.,2025-01-01,Chandler Paulette D,Pfizer,cchristopher@fas.harvard.edu.
34403429,Significance of descriptive symptoms and signs and clinical parameters as predictors of neuropathic cancer pain.,2021-01-01,Gil Ha Yeong,Pfizer Pharmaceuticals Korea,None
31775882,Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential?,2019-11-27,Potluri Shobha; Wang I-Ming; Fleener Catherine,Pfizer; Translational Science at Samumed,andrew.nixon@duke.edu.
36098654,Improving access to oncology publications for advocates and people with cancer.,2022-11-01,Chari Dheepa; Ghith Jennifer; Ferdinand Roxanne,Pfizer,None
39368039,Population Pharmacokinetic Analysis of Tucatinib in Healthy Participants and Patients with Breast Cancer or Colorectal Cancer.,2024-10-01,Zhang Daping; Endres Christopher J; Topletz-Erickson Ariel,Pfizer,Ariel.Erickson@pfizer.com.
28187516,Collaborating to Compete: Blood Profiling Atlas in Cancer (BloodPAC) Consortium.,2017-05-01,Juhl H; Martin A-M; Mulpuri R; Posadas E; Reese D; Talasaz A; Toukhy H; Tseng H R; Wolf J,Indivumed; Novartis; Provista Diagnostics; CytoLumina; Guardant Health,None
38573132,Patient engagement in designing and publishing research in prostate cancer: a scoping review.,2024-01-01,Evuarherhe Obaro,Oxford,None
36317162,The Burden of Metastatic Cancer-Induced Bone Pain: A Narrative Review.,2022-01-01,Dragon Erika,Pfizer,None
37248173,"Animal models of inflammatory bowel disease: novel experiments for revealing pathogenesis of colitis, fibrosis, and colitis-associated colon cancer.",2023-07-01,Habtezion Aida,Pfizer,None
30025274,Global analysis of metastatic breast cancer policy gaps and advocacy efforts across the patient journey.,2018-10-01,Thrift-Perry Maia; Faircloth Kyra,Pfizer,ACabanes@komen.org.
31182754,Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer.,2019-06-10,Hasa-Moreno Adela; Aschenbrenner Laura; Van Blarcom Thomas; Liu Shu-Hui,Kodiak Sciences; Covance; Allogene; Multitude,gzhu108@live.com.
39933898,Dynamics of molecular heterogeneity in high-risk luminal breast cancer-From intrinsic to adaptive subtyping.,2025-02-10,Zhang Zhe,Pfizer,carsten.denkert@uni-marburg.de.
19967539,Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.,2010-07-01,Houk Brett E,Pfizer,brett.houk@pfizer.com
37314600,Prescription patterns of analgesics in cancer patients with bone metastases in Japan: a retrospective database study.,2023-09-01,Tomitori Hideyuki; Akano Kyoko,Pfizer Japan,kyoko.akano@pfizer.com.
34846775,Application of artificial intelligence to overcome clinical information overload in urological cancer.,2022-09-01,Ghith Jenny,Pfizer,None
39481054,Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and Neck Cancer.,2025-02-10,Wozniak Michele; Zhao Yongyun; Mihm Michael; Kaplan Jason; Gorla Seema,Astellas,None
28078656,Biosimilars for the Treatment of Cancer: A Systematic Review of Published Evidence.,2017-02-01,Lula Sadiq,Envision,ira.jacobs@pfizer.com.
31907370,Effective delivery of Complex Innovative Design (CID) cancer trials-A consensus statement.,2020-02-01,Cooper Alison M; Fisher Wendy,The Association of the British,sarah.blagden@oncology.ox.ac.uk.
38332714,Effectiveness and safety of anticoagulants among patients with venous thromboembolism and active cancer who also had prior bleed or prior renal disease.,2024-03-01,Noxon Virginia; Shah Shrushti,STATinMED,None
27882192,Next-Generation Antibody-Drug Conjugates (ADCs) for Cancer Therapy.,2016-11-10,Junutula Jagath Reddy; Gerber Hans-Peter,Cellerant; Targeted,None
36848784,Trends and factors associated with outpatient anticoagulant treatment initiation among VTE patients with active cancer.,2023-04-01,Shah Shrushti; Noxon Virginia; Bruette Robert; Luo Xuemei,SIMR; Pfizer,amol.dhamane@bms.com.
38565911,Emerging racial disparities among Medicare beneficiaries and Veterans with metastatic castration-sensitive prostate cancer.,2024-12-01,Ramaswamy Krishnan; Russell David; Emir Birol; Yang Hongbo; Song Wei; Hong Agnes; Gao Wei,Pfizer; Analysis Group; Formerly of Astellas Pharma,Daniel.George@duke.edu.
36625851,Case Studies for Overcoming Challenges in Using Big Data in Cancer.,2023-04-14,Davis Gerard J; Gawel Susan H; Kirsch Ilan R; Shi George,Adaptive,None
37837178,"Impact of posaconazole and diltiazem on pharmacokinetics of encorafenib, a BRAF V600 kinase inhibitor for melanoma and colorectal cancer with BRAF mutations.",2023-12-01,Hahn Erik; Chavira Renae; Tan Weiwei,Pfizer,None
37592001,The impact of race on survival in metastatic prostate cancer: a systematic literature review.,2023-09-01,Niyazov Alexander; Nazari Jonathan,Pfizer,stephen.freedland@cshs.org.
30202448,Updates on managing advanced breast cancer with palbociclib combination therapy.,2018-01-01,McShane Teresa M; Wolfe Thomas A; Ryan Joanne C,Pfizer,None
38546943,Palbociclib in Older Patients with Advanced/Metastatic Breast Cancer: A Systematic Review.,2024-05-01,Chen Connie; Pasupuleti Vinay,Pfizer; Oxford PharmaGenesis,kgelmon@bccancer.bc.ca.
38014519,Genetic testing and counseling challenges in personalized breast cancer care: review article with insights from Türkiye.,2024-05-01,Ozturk Saglam Ozge Fulya; Aver Birkan,Pfizer,None
35236002,Evaluation of pharmacokinetics and safety of talazoparib in patients with advanced cancer and varying degrees of hepatic impairment.,2022-07-01,Guo Cen; Yu Yanke; Chakrabarti Jayeta; Moroose Rebecca; Shi Haihong; Durairaj Chandrasekar; Wang Diane D,Pfizer; Orlando Health,None
26743742,HESI/FDA workshop on immunomodulators and cancer risk assessment: Building blocks for a weight-of-evidence approach.,2016-03-01,Weinstock D,Janssen Research & Development,hlebrec@amgen.com.
31372057,A systematic review of the international prevalence of <i>BRCA</i> mutation in breast cancer.,2019-01-01,Armstrong Nigel; Ryder Steve; Forbes Carol; Ross Janine; Quek Ruben Gw,Kleijnen Systematic Reviews; Pfizer,None
34062620,The value of new drugs for advanced prostate cancer.,2021-09-15,Fox Kathleen M,Strategic Healthcare Solutions,None
38653037,Treatment Patterns and Clinical Outcomes Among Patients With Metastatic Prostate Cancer Harboring Homologous Recombination Repair Mutations.,2024-06-01,Bobbili Priyanka J; Ivanova Jasmina; DerSarkissian Maral; Chang Jane; Niyazov Alexander; Muthukumar Aruna; Guo Tracy; Mohan Manasi; Zhang Adina; Duh Mei Sheng,Analysis Group; Pfizer,Priyanka.Bobbili@analysisgroup.com.
37713020,Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer.,2023-11-01,Brown Bruce; Lu Sophia; Fallick Mark; Hanson Sarah,Myovant Sciences; Pfizer,NShore@gsuro.com.
34671701,Voice Analysis of Cancer Experiences Among Patients With Breast Cancer: VOICE-BC.,2021-01-01,Auil Maria J; Berg Kiersten,Quid,None
34604802,Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients With Active Cancer.,2021-09-01,Luo Xuemei,Pfizer,None
25123209,Antibody-drug conjugates: an emerging modality for the treatment of cancer.,2014-08-01,Leal Mauricio,Department of,None
37803017,Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study.,2023-10-06,Laird A Douglas; Chelliserry Jijumon; Chen Ying; Conte Umberto,Pfizer,Nicholas.Turner@icr.ac.uk.
27013405,The State of Lung Cancer Research: A Global Analysis.,2016-07-01,Roe Philip,Evaluametrics,ajay.aggarwal@kcl.ac.uk.
33275038,"Toxicities of axitinib, sunitinib and temsirolimus: implications for progression-free and overall survival in metastatic renal cell cancer.",2021-01-01,Woike Michael,Pfizer Pharma,None
36751300,The Saudi Consensus for the Management of Cancer-Associated Thromboembolism: A Modified Delphi-Based Study.,2023-01-01,Osman Ahmed,Pfizer,None
20691711,"An ""Omics"" based survey of human colon cancer.",2010-11-10,Nambiar Prashant R,Pfizer,prashant.nambiar@pfizer.com
36226872,Does race make a difference in how long men with advanced prostate cancer live when treated with abiraterone or enzalutamide?,2022-10-13,Schultz Neil M,Astellas,None
15922853,c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.,2005-07-08,Christensen James G,Research,james.christensen@pfizer.com
31955338,Inpatient and outpatient treatment patterns of cancer-associated thrombosis in the United States.,2020-08-01,Hlavacek P,Pfizer,Jennifer.Guo@bms.com.
28652278,Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.,2017-09-01,Loibl Sibylle; Hoffman Justin; Zhang Ke,German Breast Group GBG Forschungs; Pfizer,Sibylle.Loibl@gbg.de.
29271081,"Incidence and risk factors of postoperative pneumonia following cancer surgery in adult patients with selected solid cancer: results of ""Cancer POP"" study.",2018-01-01,Seo Bo-Jeong; Kim Young-Joo; Park Seong-Beom,Pfizer Pharmaceuticals Korea,None
36319831,Epidemiological Study Regarding the Incidence of Venous Thromboembolism in Patients After Cancer Remission.,2022-12-01,Imura Miki; Katada Jun,Pfizer Japan,miki.imura@pfizer.com.
31322208,A systematic review of the prevalence of DNA damage response gene mutations in prostate cancer.,2019-09-01,Lang Shona H; Swift Stephanie L; White Heath; Misso Kate; Kleijnen Jos; Quek Ruben G W,Kleijnen Systematic Reviews; Pfizer,None
30891558,AMPK promotes the survival of colorectal cancer stem cells.,2018-06-01,Guo Bing,Novartis,None
35118821,Effect of enzalutamide on PK of P-gp and BCRP substrates in cancer patients: CYP450 induction may not always predict overall effect on transporters.,2022-05-01,Poondru Srinivasu; Khosravan Reza; Manchandani Pooja; Heo Nakyo; Moy Selina; Wojtkowski Tomasz; Patton Melanie; Haas Gabriel P,Astellas Pharma; Pfizer,None
38234214,Disparities in care of older adults of color with cancer: A narrative review.,2024-02-01,Ryan Joanne C,Pfizer,None
37014080,Real-World Treatment Trends Among Patients with Metastatic Castration-Sensitive Prostate Cancer: Results from an International Study.,2023-09-07,Ivanova Jasmina; Niyazov Alexander,Pfizer,None
30111973,Real-world patient- and caregiver-reported outcomes in advanced breast cancer.,2018-08-01,Lambert-Obry V; Gouault-Laliberté A; Castonguay A; Zanotti G; Lachaine J,PeriPharm; Pfizer,None
38143206,Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study.,2024-08-01,Hanson Sarah; Brown Bruce; Lu Sophia; Fallick Mark,Pfizer; Myovant Sciences,rtutrone@uniteduro.com.
35471070,The cost impact of disease progression to metastatic castration-sensitive prostate cancer.,2022-05-01,Chaves Leonardo Passos; Feng Qi; Zhu Julia; Abbott Thomas,Astellas,None
37662184,Order-of-mutation effects on cancer progression: models for myeloproliferative neoplasm.,2023-08-22,Shtylla Blerta,Quantitative Systems,None
37645049,Order-of-mutation effects on cancer progression: models for myeloproliferative neoplasm.,2023-08-19,Shtylla Blerta,Quantitative Systems,None
31011205,Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial.,2019-05-01,Afshar Mohammad; Martini Jean-François,Ariana; Pfizer,rkurzrock@ucsd.edu.
39235063,Patterns and outcomes in HR+/HER2- advanced/metastatic breast cancer patients in Brazil receiving palbociclib.,2024-01-01,Simon Patricia; Jain Ankita; Guarin Alexandra; Piton Luciana,Pfizer,None
37185407,Psychosocial Wellbeing among Patients with Breast Cancer during COVID-19.,2023-03-30,Liu Xianchen; Kurosky Samantha K; Li Benjamin; McRoy Lynn,Pfizer,None
26541643,"Risk of gastric cancer, gastrointestinal cancers and other cancers: a comparison of treatment with pantoprazole and other proton pump inhibitors.",2016-01-01,Kolitsopoulos F,Pfizer,None
31668001,Incidence rates of cardiovascular outcomes in a community-based population of cancer patients.,2019-12-01,Titievsky Lina,Pfizer,None
32020841,Budget Impact of Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.,2020-04-01,Schultz Neil M,Astellas,None
20141331,A survey of cancer cell lines reveals highly structured and hierarchical relationships within and between DNA and mRNA that may be the result of selection.,2010-02-01,Xie Tao,Rosetta Inpharmatics,Tao.Xie@pfizer.com
31535940,Effect of DNA damage response mutations on prostate cancer prognosis: a systematic review.,2019-10-01,Swift Stephanie L; Lang Shona H; White Heath; Misso Kate; Kleijnen Jos; Quek Ruben Gw,Kleijnen Systematic Reviews; Pfizer,None
15758351,Skeletal implications of prostate cancer.,2003-06-01,Bagi C M,Pfizer,cedo_bagi@groton.pfizer.com
32691438,Discordance Between Child-Pugh and National Cancer Institute Classifications for Hepatic Dysfunction: Implications on Dosing Recommendations for Oncology Compounds.,2021-01-01,Elmeliegy Mohamed; Yang Derek Z; Salama Engie; Parivar Kourosh; Wang Diane D,Pfizer; Skaggs School of Pharmacy &,None
37139257,Patient Willingness to Use Digital Health Technologies: A Quantitative and Qualitative Survey in Patients with Cancer Cachexia.,2023-01-01,Tarasenko Lisa; LaRonde-Richard Ann-Marie; Kessler Nancy; Rossulek Michelle; Plate Hans; Mahoney Kim,Pfizer; Pensari,None
34256965,Health-Related Quality of Life Among Patients With HR+/HER2- Early Breast Cancer.,2021-07-01,Spurden Dean,Pfizer,None
19963098,Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.,2009-12-01,Gibbons James J,Pfizer,gibbonj@wyeth.com
39661316,Correction: Population Pharmacokinetic Analysis of Tucatinib in Healthy Participants and Patients with Breast Cancer or Colorectal Cancer.,2025-01-01,Zhang Daping; Endres Christopher J; Topletz-Erickson Ariel,Pfizer,Ariel.Erickson@pfizer.com.
31066140,Health-related quality of life associated with different cancer treatments in Chinese breast cancer survivors in Taiwan.,2019-07-01,Wen Yao-Chun; Fang Wei-Tse,Pfizer PFE,None
31128428,Development of predictive models to identify advanced-stage cancer patients in a US healthcare claims database.,2019-08-01,Yin Ruihua; Desai Vibha C A; Lyons Jennifer G; Lanes Stephan,HealthCore,slanes@healthcore.com.
35350106,Awareness and Availability of Routine Germline <i>BRCA1/2</i> Mutation Testing in Patients with Advanced Breast Cancer in Germany.,2022-02-01,Runkel Eva Diana; Niyazov Alexander; Quek Ruben G W,Pfizer Pharma; Pfizer,None
36199494,Timely Genetic Testing and Therapy Management in Patients With g<i>BRCA</i>-Mutated Metastatic Breast Cancer Receiving Talazoparib.,2022-09-01,Ryan Joanne C; Barnett Chad M; Soussou Elpitha L,Pfizer,None
22077502,Putting the cardiovascular safety of aromatase inhibitors in patients with early breast cancer into perspective: a systematic review of the literature.,2011-12-01,Younus Muhammad,Pfizer,None
29229993,Therapeutic relevance of the PP2A-B55 inhibitory kinase MASTL/Greatwall in breast cancer.,2018-05-01,VanArsdale Todd; Shields David,Pfizer,malumbres@cnio.es.
32460197,Ophthalmological assessment of crizotinib in advanced non-small-cell lung cancer.,2020-07-01,Monti Katherine,Rho,ben.solomon@petermac.org.
38201491,Financial Toxicity among Patients with Breast Cancer during the COVID-19 Pandemic in the United States.,2023-12-21,Wu Yan; Liu Xianchen; Li Benjamin; McRoy Lynn,Ernest Mario School of; Pfizer,None
38298745,Implications of Delayed Testosterone Recovery in Patients with Prostate Cancer.,2024-02-01,Hong Agnes; Dufour Robert; Marden Jessica R; Kirson Noam Y; Gatoulis Sergio C; Kongara Serena; Gandhi Raj,Pfizer; Myovant Sciences; Analysis Group,None
28463012,Comparison of palbociclib in combination with letrozole or fulvestrant with endocrine therapies for advanced/metastatic breast cancer: network meta-analysis.,2017-08-01,Mitra Debanjali; Iyer Shrividya,b Pfizer,None
28318331,Docetaxel chemotherapy in metastatic castration-resistant prostate cancer: cost of care in Medicare and commercial populations.,2017-06-01,Bui C; Fitch K; Sawhney T Goss; Brown B; Flanders S; Balk M; Deangelis J,b Astellas; c Milliman; d Formerly of Medivation,None
37882319,Heterogeneous distributions in clinical events preceding anticoagulant treatment nonpersistence in patients with venous thromboembolism stratified by active cancer: A nationwide cohort study.,2023-11-01,Choi Songhwa; Lee Daye,Pfizer Korea,None
35218313,Addressing unmet needs for people with cancer cachexia: recommendations from a multistakeholder workshop.,2022-04-01,Birnbaum Morris J,Pfizer,None
35191170,Utilizing restricted mean duration of response for efficacy evaluation of cancer treatments.,2022-09-01,Huang Bo,Pfizer,None
38135714,"The impact of circulating protein levels identified by affinity proteomics on short-term, overall breast cancer risk.",2024-03-01,Huang Tzu-Hsuan,Pfizer,felix.grassmann@ki.se.
39077892,"Identification of the Clinical Candidate <b>PF-07284890</b> (<b>ARRY-461</b>), a Highly Potent and Brain Penetrant BRAF Inhibitor for the Treatment of Cancer.",2024-08-08,Ren Li; Moreno David; Barbour Patrick; Bettendorf Tanna; Bouhana Karyn; Fell Jay B,Enliven,None
32194831,Targeting microtubules sensitizes drug resistant lung cancer cells to lysosomal pathway inhibitors.,2020-01-01,Settleman Jeff,Pfizer,None
23820871,Combined gemcitabine and CHK1 inhibitor treatment induces apoptosis resistance in cancer stem cell-like cells enriched with tumor spheroids from a non-small cell lung cancer cell line.,2013-12-01,Fang Douglas D,Pfizer,douglasfang@yahoo.com.
37487056,Real-World Effectiveness of Palbociclib Plus Aromatase Inhibitors in African American Patients With Metastatic Breast Cancer.,2023-10-03,Liu Xianchen; Li Benjamin; McRoy Lynn; Chen Connie,Pfizer,None
29983880,Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer.,2018-06-19,Veeneman Brendan A; Wang Yipeng; Jendrisak Adam; Graf Ryon P; Dittamore Ryan,Pfizer; Epic Sciences,None
25592564,Cell Index Database (CELLX): a web tool for cancer precision medicine.,2015-01-01,Ching Keith A,Pfizer,keith.ching@pfizer.com.
19826365,Other paradigms: health-related quality of life as a measure in cancer treatment: its importance and relevance.,2009-01-01,Trask Peter C,Pfizer,Peter.C.Trask@Pfizer.com
33498797,Real-World Palbociclib Use in HR+/HER2- Advanced Breast Cancer in Canada: The IRIS Study.,2021-01-24,Zhan Lin; Mitra Debanjali,Pfizer,None
30767568,Current situation and challenges regarding biosimilars in Japan: an example of trastuzumab biosimilars for breast cancer.,2019-04-01,Tajima Kentaro; Tanabe Kosuke,Pfizer Japan,None
38363386,Order-of-Mutation Effects on Cancer Progression: Models for Myeloproliferative Neoplasm.,2024-02-16,Shtylla Blerta,Pharmacometrics and Systems,tomchou@ucla.edu.
15758396,Cancer cell metastases.,2002-12-01,Bagi C M,Pfizer,cedo_bagi@groton.pfizer.com
39813906,Racial Differences in Survival and Healthcare Resource Utilization Among Medicaid-Insured Adults With Metastatic Prostate Cancer.,2025-04-01,DerSarkissian Maral; Gupta Deepshekhar; Ivanova Jasmina; Niyazov Alexander; Zanardo Enrico; Guo Tracy; Wang Jingru; Duh Mei Sheng,Analysis Group; Pfizer; Flatiron Health,Maral.DerSarkissian@Analysisgroup.com.
36226865,Which traits affect how long patients with advanced prostate cancer live when treated with enzalutamide?,2022-11-01,Steinberg Joyce; Sugg Jennifer,Astellas Pharma,None
30352060,Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China.,2018-01-01,Fu Shijun; Ren Hongye,Pfizer China,None
27015560,mTOR complex-2 stimulates acetyl-CoA and de novo lipogenesis through ATP citrate lyase in HER2/PIK3CA-hyperactive breast cancer.,2016-05-03,Toral-Barza Lourdes; Shi Celine; Wu Jiang,Pfizer,None
26498688,PIK3CA mutation detection in metastatic biliary cancer using cell-free DNA.,2015-11-24,Lira Maruja; Deng Shibing,Pfizer,None
21750698,Predictive genes in adjacent normal tissue are preferentially altered by sCNV during tumorigenesis in liver cancer and may rate limiting.,2011-01-01,Lamb John R,Rosetta Inpharmatics,john.lamb@pfizer.com
39503549,Plain language review: the safety of relugolix combination therapy for advanced prostate cancer.,2025-01-01,Flanders Scott C; Gatoulis Sergio C,Sumitomo Pharma America; Pfizer,None
29946798,Patterns of Bicalutamide Use in Prostate Cancer Treatment: A U.S. Real-World Analysis Using the SEER-Medicare Database.,2018-09-01,Schultz Neil M; Flanders Scott C; Barlev Arie; Quek Ruben G W,Astellas Pharma; Pfizer,dimmerj@karmanos.org.
30207163,Treatment satisfaction in women receiving palbociclib combination therapies for advanced/metastatic breast cancer.,2019-01-01,Mitra Debanjali; Iyer Shrividya,Pfizer,None
29796165,Preclinical evaluation of a GFRA1 targeted antibody-drug conjugate in breast cancer.,2018-05-01,Bosco Emily E; Christie R James; Carrasco Rosa; Sabol Darrin; Zha Jiping; DaCosta Karma; Brown Lee; Kennedy Maureen; Meekin John; Phipps Sandrina; Ayriss Joanne; Du Qun; Bezabeh Binyam; Chowdhury Partha; Breen Shannon; Chen Cui; Reed Molly; Hinrichs MaryJane; Zhong Haihong; Xiao Zhan; Dixit Rakesh; Herbst Ronald; Tice David A,MedImmune,None
37141847,"A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer.",2023-06-01,Poddubskaya E V,Vitamed,galffy.gabriella@torokbalintkorhaz.hu.
24376576,Exome sequencing identifies early gastric carcinoma as an early stage of advanced gastric cancer.,2013-01-01,Wang Kai,Pfizer,None
30002437,Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer.,2018-08-01,Hilton Fiona; Coppola Jennifer; Jacobs Ira,Pfizer,ira.jacobs@pfizer.com.
15758355,Intra-tibial injection of human prostate cancer cell line CWR22 elicits osteoblastic response in immunodeficient rats.,2003-06-01,Andersen C,Pfizer,cedo_bagi@groton.pfizer.com
19058146,Future perspectives on the treatment issues associated with cancer and aging.,2008-12-15,Trask Peter C,Pfizer,peter.c.trask@pfizer.com
34589999,Real-World Evidence of Diagnostic Testing for Driver Oncogene Mutations in Lung Cancer in Japan.,2021-03-01,Yoshiki Yasumasa; Matsumura Koichi; Togo Kanae; Kikkawa Hironori; Iadeluca Laura; Li Benjamin,Pfizer Japan; Pfizer,None
26716558,OASIS: web-based platform for exploring cancer multi-omics data.,2016-01-01,Fernandez-Banet Julio; Esposito Anthony; Coffin Scott; Horvath Istvan Boerner; Estrella Heather; Schefzick Sabine; Deng Shibing; Wang Kai; AChing Keith; Ding Ying; Roberts Peter; Rejto Paul A; Kan Zhengyan,Pfizer,None
36251491,BLOODPAC: Collaborating to chart a path towards blood-based screening for early cancer detection.,2023-01-01,Clarke Christina A; McDole Jeremiah,GRAIL; Bio-Rad Laboratories,None
23965809,Regulatory Forum commentary: alternative mouse models for future cancer risk assessment.,2014-07-01,Morton Daniel; Nambiar Prashant R; Turner Oliver C; Radi Zaher; Bower Nancy,Pfizer; Novartis; Eisai,dan.g.morton@pfizer.com.
31778074,"Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer.",2020-01-01,Salgia Ravi,Department of Medical Oncology &,None
21980324,miRNA Alterations Modify Kinase Activation In The IGF-1 Pathway And Correlate With Colorectal Cancer Stage And Progression In Patients.,2011-01-01,Knowlton David L,Pfizer,None
17289896,Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy.,2007-02-01,Yin Donghua,Pfizer,None
38682677,Impact of COVID-19 on patients with metastatic breast cancer: REthink Access to Care and Treatment survey results.,2024-01-01,Williams Clay; Rogan Michael; Block Jeremy,Greenphire,None
33993815,Exposure-response modeling of the effect of glasdegib on cardiac repolarization in patients with cancer.,2021-07-01,Fostvedt Luke K; Shaik Naveed; Ruiz-Garcia Ana,Pfizer,None
28588760,The impact of database restriction on pharmacovigilance signal detection of selected cancer therapies.,2017-05-01,Hung Eric; Wood Jennifer; Soitkar Amit; Reshef Daniel,Pfizer; Global,None
37755611,Correction to: Epidemiological Study Regarding the Incidence of Venous Thromboembolism in Patients After Cancer Remission.,2023-12-01,Imura Miki; Katada Jun,Pfizer Japan,miki.imura@pfizer.com.
27084424,Upregulation of RNA Processing Factors in Poorly Differentiated Lung Cancer Cells.,2016-04-01,Geles Kenneth G; Zhong Wenyan; O'Brien Siobhan K; Baxter Michelle; Loreth Christine; Damelin Marc,Pfizer,marc.damelin@pfizer.com.
26716514,Functional genomics screen identifies YAP1 as a key determinant to enhance treatment sensitivity in lung cancer cells.,2016-05-17,Yu Jiyang,Pfizer,None
39466588,Perspectives on Drug Product Design Among Patients with Lung Cancer in the United Kingdom.,2024-12-01,Baig Louis Edward; Ogden-Barker Michaela; Doody Colm,Pfizer,albert.hauber@pfizer.com.
27281559,Clinical Implications of the Pharmacokinetics of Crizotinib in Populations of Patients with Non-Small Cell Lung Cancer.,2016-12-01,Nickens Dana J; Amantea Michael,Pfizer,Erjian.Wang@pfizer.com.
29417827,Validating the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer: data from TRUMPET.,2018-03-01,Flanders Scott C; Kim Janet; Wilson Samuel; Braziunas Jeffrey; Lechpammer Stanislav,Astellas; Medivation,None
39284628,"Nonclinical Profile of PF-06952229 (MDV6058), a Novel TGFβRI/Activin Like Kinase 5 Inhibitor Supports Clinical Evaluation in Cancer.",2024-10-18,Guha Mausumee; Thibault Stephane; Pham Son; Bernales Sebastian; Pai Rama; Herrera Francisco J; Johnson Theodore R; Vitsky Allison; Fernando Tina; Finkelstein Martin,cBio,mausumee.guha@yahoo.com.
40145289,Overall Survival With Palbociclib and Aromatase Inhibitor Versus Aromatase Inhibitor Alone in Older Patients With HR+/HER2- Metastatic Breast Cancer.,2025-04-01,Stergiopoulos Stella; Chen Connie; Li Benjamin; Makari Doris,Pfizer,None
32013416,Quantitation of Urinary Acylcarnitines by DMS-MS/MS Uncovers the Effects of Total Body Irradiation in Cancer Patients.,2020-03-04,Vera Nicholas B; Clasquin Michelle; Pfefferkorn Jeffrey A,Pfizer,None
29360661,Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer.,2018-03-01,Durairaj Chandrasekar; Ruiz-Garcia Ana; Gauthier Eric R; Huang Xin; Lu Dongrui R; Hoffman Justin T; Zheng Jenny; Wilner Keith D; Wang Diane D,Pfizer,None
21540235,Delineation of a cellular hierarchy in lung cancer reveals an oncofetal antigen expressed on tumor-initiating cells.,2011-06-15,Damelin Marc,Pfizer,marc.damelin@pfizer.com
33192078,Treatment Sequencing Patterns in Patients with Metastatic Urothelial Cancer Treated in the Community Practice Setting in the United States: SPEAR-Bladder (Study informing treatment Pathway dEcision in bladder cAnceR).,2020-01-01,Cislo Paul; Kim Ruth,Pfizer,None
24298897,Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer.,2014-12-01,Leopold Lance; Wood Brian A; Wang Shaw-Ling; Paolini Jolanda; Chen Isan; Chow-Maneval Edna; Lechuga Mariajose,Ascenta; Pfizer; ICON Clinical Research; Seragon,None
20953153,The path to developing a cervical cancer vaccine.,2010-10-01,Jansen Kathrin U,Pfizer,kathrin.jansen@pfizer.com
39483875,Assessing racial differences in time to subsequent treatment following androgen deprivation therapy among Veterans with prostate cancer.,2024-10-18,Hong Agnes,Pfizer,None
39167332,Patient Preferences for Attributes of Androgen Deprivation Therapies in Prostate Cancer: A Discrete Choice Experiment with Latent Class Analysis.,2024-10-01,Hauber Brett; Hong Agnes; Hunsche Elke,Pfizer; Sumitomo Pharma Switzerland,Sean.P.Collins@gunet.georgetown.edu.
27436663,Economic Analysis Comparing Dalteparin to Vitamin K Antagonists to Prevent Recurrent Venous Thromboembolism in Patients With Cancer Having Renal Impairment.,2016-10-01,Dranitsaris George,Augmentium Pharma Consulting,george@augmentium.com.
20704980,Cell surface growth factor receptor molecules as targets for cancer therapy.,2004-06-01,Fischer Oliver M,Pfizer,None
17398092,The discovery of highly selective erbB2 (Her2) inhibitors for the treatment of cancer.,2007-06-01,Lippa Blaise,Pfizer,blaise.lippa@pfizer.com
27202198,Costs of Pneumonia in Patients With Cancer Diagnosis from the Private Health System Perspective in Brazil.,2014-11-01,Manfrin D F; Ferreira C N; Gea Y; Rufino C S,Pfizer,None
15758399,Cancer of the prostate - implication for bone metastases.,2002-12-01,Bagi C M,Pfizer,cedo_bagi@groton.pfizer.com
33989949,Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer.,2021-06-01,Moran Michael,Pfizer Pharma,Jean.Bourhis@chuv.ch.
37665777,"Left Ventricular Ejection Fraction in Patients With Ovarian Cancer Treated With Avelumab, Pegylated Liposomal Doxorubicin, or Both.",2023-10-03,Moran Michael,Pfizer Pharma,None
37308665,The GPCR-Gα<sub>s</sub>-PKA signaling axis promotes T cell dysfunction and cancer immunotherapy failure.,2023-08-01,Wu Victoria H,Department of; Septerna,Bio@SNS
39095951,The mortality burden of cachexia or weight loss in patients with colorectal or pancreatic cancer: A systematic literature review.,2024-10-01,Smoyer Karen E,Envision,None
26407753,Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial.,2015-12-01,Lee T C; Pak R; Yamabe T,Pfizer,None
37186518,Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer.,2023-07-05,Lee Catherine; Jiang Ziyue Karen; Planken Simon; Manzuk Lisa K; Ortiz Roberto; Hall Michael; Noorbehesht Kavon; Ram Sripad; Affolter Timothy; Troche Gabriel E; Ihle Nathan T; Johnson Theodore; Ahn Youngwook; Kraus Manfred; Giddabasappa Anand,Pfizer; Drug Safety Research and Development Pfizer,None
39329173,Identifying and addressing the needs of caregivers of patients with cancer: evidence on interventions and the role of patient advocacy groups.,2024-01-01,Dave Rushi; Wolf Gianares Brittany; Wilson Tracy,Pfizer,None
37395248,Cancer incidence and mortality trends in Asia based on regions and human development index levels: an analyses from GLOBOCAN 2020.,2023-08-01,Singh Manmohan,Pfizer Corporation Hong Kong,None
33471574,Treatment Patterns and Clinical Outcomes in Korean Cancer Patients With Venous Thromboembolism: A Retrospective Cohort Study.,2021-01-01,Kim Young-Joo; Gil Ha-Yeong,Pfizer Pharmaceuticals Korea,None
38035646,Novel hormone therapy and coordination of care in high-risk biochemically recurrent prostate cancer.,2024-01-01,Bland Christopher S,Pfizer,jefstathiou@partners.org.
39530636,Using bioinformatics and artificial intelligence to map the cyclin-dependent kinase 4/6 inhibitor biomarker landscape in breast cancer.,2024-12-01,Wager Kim; Wang Yao; Liew Andrew; Campbell Dean; Liu Feng; Martini Jean-François; Ziaee Niusha; Liu Yuan,Oxford PharmaGenesis; Pfizer,None
38488039,Evaluating relugolix for the treatment of prostate cancer in real-world settings of care: the OPTYX study protocol.,2024-04-01,Fallick Mark; Flanders Scott C,Myovant Sciences,None
36721313,Deep learning-based pathology image analysis predicts cancer progression risk in patients with oral leukoplakia.,2023-03-01,Papadimitrakopoulou Vassiliki,Pfizer,None
27891226,Validation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerations.,2016-01-01,Cesano Alessandra; Alvarez John; Hawtin Rachael; Janetzki Sylvia; Kirsch Ilan; Selvan Senthamil R; Zhang Jenny,NanoString; Janssen Research & Development; Nodality; ZellNet Consulting; Adaptive; Omni Array; Covaris,None
16686369,Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse.,2006-01-01,Zaher Hani,Department of,hani.zaher@pfizer.com
35306859,Real-world treatment patterns of palbociclib and blood count monitoring in patients with advanced breast cancer in Japan.,2022-06-01,Muramatsu Yasuaki; Togo Kanae,Pfizer Japan,None
39073610,Treatment patterns and outcomes in patients with nonmetastatic castration-resistant prostate cancer in the United States.,2024-01-01,Hong Agnes; Young Christopher; Xie Bin; Ramaswamy Krishnan; El Chaar Nader,Astellas Pharma; Pfizer,None
37982848,"A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia.",2024-02-01,Collins Susie M,Pfizer R&D UK,None
36751989,Real-world study of next-generation sequencing diagnostic biomarker testing for patients with lung cancer in Japan.,2023-06-01,Emir Birol; Iadeluca Laura,Pfizer,None
30642312,"Burden of community-acquired pneumonia, predisposing factors and health-care related costs in patients with cancer.",2019-01-14,Theilacker Christian,Pfizer Deutschland,niklas.schmedt@ingef.de.
35091441,"Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer.",2022-04-01,Laird A Douglas; Chen Ying; Lanzalone Silvana; Chelliserry Jijumon; Czibere Akos,Pfizer,None
39095766,Real-world dosing of regorafenib and outcomes among patients with metastatic colorectal cancer: a retrospective analysis using US claims data.,2024-08-02,Khan Nasreen; Jiao XiaoLong; Chen Guifang; Lin Wenlong; Bruno Amanda,Bayer HealthCare,Bekaii-Saab.Tanios@Mayo.edu.
34164937,Quantitative prediction of breast cancer resistant protein mediated drug-drug interactions using physiologically-based pharmacokinetic modeling.,2021-09-01,Costales Chester; Lin Jian; Kimoto Emi; Yamazaki Shinji; Gosset James R; Rodrigues A David; Lazzaro Sarah; West Mark A; Varma Manthena V S,Pfizer,None
27979599,Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis.,2017-01-01,Murphy Martin; Morrell Joseph; Lebowitz Peter,Project Data Sphere; the,atf2116@cumc.columbia.edu.
34732856,Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer.,2022-09-01,Ramaswamy Krishnan; Russell David; Mardekian Jack; Schultz Neil M,Pfizer; Astellas,daniel.george@duke.edu.
32468579,Talazoparib Exposure-Efficacy Analysis in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA Trial.,2020-10-01,Yu Yanke; Elmeliegy Mohamed; Tudor Iulia Cristina; Czibere Akos; Wang Diane D,Pfizer,None
39003108,Risk of cardiovascular events following intermittent and continuous androgen deprivation therapy in patients with nonmetastatic prostate cancer.,2024-12-01,Hong Agnes; Gandhi Raj; Hanson Sarah; Dufour Robert,Pfizer; Myovant Sciences,mpreston@bwh.harvard.edu.
27895917,Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.,2016-01-01,Kirsch Ilan; Alvarez John; Selvan Senthamil R,Adaptive; Janssen Research & Development; Omni Array,None
32468645,Exposure-Safety Analyses of Talazoparib in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA and ABRAZO Trials.,2020-10-01,Elmeliegy Mohamed; Yu Yanke; Czibere Akos; Wilson Gary G; Tudor Iulia Cristina; Wang Diane D,Pfizer,None
39024212,Health disparities in cervical cancer: Estimating geographic variations of disease burden and association with key socioeconomic and demographic factors in the US.,2024-01-01,Ting Jie; Zhang Yitong J; Moore Kathleen,Pfizer,None
30652510,Comparison of cardiovascular effects of crizotinib and chemotherapy in ALK-positive advanced non-small-cell lung cancer.,2019-04-01,Kim Elizabeth E,Pfizer,None
30630678,The Effect of Polymorphism in UGT1A4 on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Patients With Breast Cancer in China.,2019-04-01,Han Mei,Pfizer Investment Co,drmafei@126.com.
31587137,Adverse Events Associated with Cumulative Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims Analysis.,2020-01-01,Schultz Neil M; Wilson Samuel; Song Yan; Yang Hongbo; Ramaswamy Krishnan,Astellas Pharma; Analysis Group; Pfizer,neil.schultz@astellas.com.
31700121,Author Correction: Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer.,2019-11-08,Hasa-Moreno Adela; Aschenbrenner Laura; Van Blarcom Thomas; Liu Shu-Hui,Kodiak Sciences; Covance; Allogene; Multitude,gzhu108@live.com.
37014097,Real-World Treatment Patterns Among Patients With Metastatic Castration-Resistant Prostate Cancer: Results From an International Study.,2023-09-07,Ivanova Jasmina; Niyazov Alexander,Pfizer,None
37529919,Real-world outcomes of patients with metastatic endocrine-responsive breast cancer receiving palbociclib-based combinations.,2023-07-01,Mazursky Orr Friedman; Shalev Hadas,Pfizer,None
39151451,Effectiveness and Safety of Extended Treatment Apixaban Versus Low-Molecular-Weight Heparin in Cancer-Associated Venous Thromboembolism.,2024-08-01,Luo Xuemei,Pfizer,None
30117060,Correction to: Patterns of Bicalutamide Use in Prostate Cancer Treatment: A U.S. Real-World Analysis Using the SEER-Medicare Database.,2018-09-01,Schultz Neil M; Flanders Scott C; Barlev Arie; Quek Ruben G W,Astellas Pharma; Pfizer,dimmerj@karmanos.org.
28138260,Dalteparin versus vitamin K antagonists for the prevention of recurrent venous thromboembolism in patients with cancer and renal impairment: a Canadian pharmacoeconomic analysis.,2017-01-01,Dranitsaris George,Augmentium Pharma Consulting,None
28474673,Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer.,2017-05-05,Kan Zhengyan,Pfizer,None
38538879,Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer.,2024-12-01,Ramaswamy Krishnan; Yang Hongbo; Liu Qing; Zhang Adina; Greatsinger Alexandra; Ivanova Jasmina; Thompson Betty; Emir Birol; Hong Agnes,Pfizer; Analysis Group; Formerly of Astellas,daniel.george@duke.edu.
39404227,Enzalutamide in metastatic hormone-sensitive prostate cancer: A plain language summary of the ARCHES and ENZAMET follow-up studies.,2025-01-01,Haas Gabriel P; Bland Christopher,Astellas Pharma; Formerly of Pfizer,None
33263430,DNA damage repair gene mutation testing and genetic counseling in men with/without prostate cancer: a systematic review.,2021-03-01,Armstrong Nigel; Quek Ruben Gw; Ryder Steve; Ross Janine; Buksnys Titas; Forbes Carol; Fox Kathleen M,Kleijnen Systematic Reviews; Pfizer; Strategic Healthcare Solutions,None
34570988,Liquid biopsy from research to clinical practice: focus on non-small cell lung cancer.,2021-11-01,Jantus-Lewintre Eloísa,Department of,None
31822716,Evaluation of the dual mTOR/PI3K inhibitors Gedatolisib (PF-05212384) and PF-04691502 against ovarian cancer xenograft models.,2019-12-10,Kan Julie,Pfizer Translational,simon.langdon@ed.ac.uk.
39863775,"Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial.",2025-03-01,Beyzarov Elena; Zhang Xiaoxi; Ferrier Graham; Zhang Xiaosong,Pfizer,SKopetz@mdanderson.org.
28280092,A Phase I/Ib Study of Enzalutamide Alone and in Combination with Endocrine Therapies in Women with Advanced Breast Cancer.,2017-08-01,Yardley Denise A; Burris Howard A; Peterson Amy C; Blaney Martha E; Steinberg Joyce L; Gibbons Jacqueline A,Medivation; Astellas,trainat@mskcc.org.
33631973,"Real-world symptoms, disease burden, resource use and quality of life in US patients with advanced renal cell cancer.",2021-06-01,Liu Frank X,EMD Serono,None
37882974,Overall survival in Japanese patients with ER+/HER2- advanced breast cancer treated with first-line palbociclib plus letrozole.,2024-01-01,Ichikawa Akemi; Muramatsu Yasuaki,Pfizer Japan,masato.takahashi0725@gmail.com.
35080190,Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design.,2022-02-01,Paccagnella Maria Luisa; Santo Nicola Di; Elmeliegy Mohamed; Lin Xun; Czibere Akos,Pfizer,None
33028084,Exploratory analysis of the platelet-to-lymphocyte ratio prognostic value in the adjuvant renal cell cancer setting.,2021-02-01,Martini Jean-François; Lin Xun,Pfizer,None
33202977,"Bioanalytical Assay Development and Validation for the Pharmacokinetic Study of GMC1, a Novel FKBP52 Co-chaperone Inhibitor for Castration Resistant Prostate Cancer.",2020-11-13,Ekpenyong Oscar; Cooper Candace,Department of,None
30687083,Erythropoiesis-Stimulating Agents in the Management of Anemia in Chronic Kidney Disease or Cancer: A Historical Perspective.,2018-01-01,Fung Selwyn; Arantes Luiz H,Pfizer,None
39168093,HSD3B1 genotype and outcomes in metastatic hormone-sensitive prostate cancer with androgen deprivation therapy and enzalutamide: ARCHES.,2024-08-20,Wozniak Michele; Zohren Fabian; Sugg Jennifer; Haas Gabriel P,Astellas Pharma; Pfizer,nimasharifi@miami.edu.
39427229,Comparative efficacy and safety of talazoparib plus enzalutamide and other first-line treatments for metastatic castration-resistant prostate cancer.,2025-03-10,Nazari Jonathan; Niyazov Alexander,Pfizer,None
38500292,Phase 2 study of the efficacy and safety of ponsegromab in patients with cancer cachexia: PROACC-1 study design.,2024-06-01,Collins Susie M,Pfizer R&D UK,None
28204995,Dalteparin or vitamin K antagonists to prevent recurrent venous thromboembolism in cancer patients: a patient-level economic analysis for France and Austria.,2017-07-01,Dranitsaris George,Augmentium Pharma Consulting,george@augmentium.com.
39651809,"Discovery of PF-07265028, A Selective Small Molecule Inhibitor of Hematopoietic Progenitor Kinase 1 (HPK1) for the Treatment of Cancer.",2024-12-26,Gallego Rebecca A; Cho-Schultz Sujin; Del Bel Matthew; Dechert-Schmitt Anne-Marie; Donaldson Joyann S; He Mingying; Jalaie Mehran; Kania Rob; Matthews Jean; McTigue Michele; Tuttle Jamison B; Risley Hud; Zhou Dahui; Zhou Ru; Ahmad Omar K; Bernier Louise; Berritt Simon; Braganza John; Chen Zecheng; Cianfrogna Julie A; Collins Michael; Costa Jones Cinthia; Cronin Ciaran N; Davis Carl; Dress Klaus; Edwards Martin; Farrell William; France Scott P; Grable Nicole; Johnson Eric; Johnson Ted W; Jones Rhys; Knauber Thomas; Lafontaine Jennifer; Loach Richard P; Maestre Michael; Miller Nichol; Moen Mark; Monfette Sebastien; Morse Peter; Nager Andrew Ross; Niosi Mark; Richardson Paul; Rohner Allison K; Sach Neal W; Timofeevski Sergei; Tucker Joseph W; Vetelino Beth; Zhang Lei; Nair Sajiv K,Pfizer,None
34725947,Treatment patterns and survival in metastatic castration-sensitive prostate cancer in the US Veterans Health Administration.,2021-12-01,Emir Birol; Hong Agnes; Serfass Lucile,Pfizer; Astellas,None
34518652,Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trials.,2022-02-01,Ganguli Arijit; Bhadauria Hemant; Holmstrom Stefan,Astellas Pharma,fred.saad@umontreal.ca.
30700828,Combining CDK4/6 inhibition with taxanes enhances anti-tumor efficacy by sustained impairment of pRB-E2F pathways in squamous cell lung cancer.,2019-05-01,Cao Joan; Zhu Zhou; Nichols Timothy C; Deng Shibing; Rejto Paul A; VanArsdale Todd; Hardwick James S; Weinrich Scott L; Wei Ping,Pfizer,ping.wei@pfizer.com.
24806399,Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer.,2014-10-01,Chen Isan; Chow-Maneval Edna,Pfizer,gsonpavde@uabmc.edu.
30804692,Systematic review of sequencing of ALK inhibitors in <i>ALK</i>-positive non-small-cell lung cancer.,2019-01-01,Chioda Marc; Torgersen Knut Martin; Masters Elizabeth T,Pfizer,sbarrows@rti.org.
33494720,Real-world safety of palbociclib in breast cancer patients in the United States: a new user cohort study.,2021-01-25,Beachler Daniel C; de Luise Cynthia; Jamal-Allial Aziza; Yin Ruihua; Taylor Devon H; Lanes Stephan,HealthCore; Pfizer; Anthem,dbeachler@healthcore.com.
38468440,The relationship between weight gain during chemotherapy and outcomes in patients with advanced non-small cell lung cancer.,2024-06-01,Hilton Fiona; Yang Ruoyong; Whalen Ed; Tarasenko Lisa,Pfizer,None
29909880,Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome Measures: Summary of an FDA and Critical Path Institute Workshop.,2018-06-01,Cappelleri Joseph C; Rubin Eric H,Pfizer,paul.kluetz@fda.hhs.gov.
34420037,"Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk.",2022-02-01,Rosbrook Brad; Lee Ho-Jin; Haas Gabriel P,Pfizer; Astellas Pharma,andrew.armstrong@duke.edu.
36324736,Comorbidity between lung cancer and COVID-19 pneumonia: role of immunoregulatory gene transcripts in high <i>ACE2</i>-expressing normal lung.,2022-01-01,Martini Jean-François,Pfizer,None
35098723,Real-world multi-country study of <i>BRCA1/2</i> mutation testing among adult women with HER2-negative advanced breast cancer.,2022-03-01,Niyazov Alexander,Pfizer,None
38861216,Development of a Novel Patient-Reported Outcome Measure to Assess Symptoms and Impacts of Androgen Deprivation Therapy for Advanced Prostate Cancer.,2024-08-01,de Paauw-Holt Simon; Hunsche Elke,Sumitomo Pharma Switzerland,elke.hunsche@ch.sumitomo-pharma.com.
35708696,Enzalutamide Monotherapy vs Active Surveillance in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial.,2022-08-01,Siddiqui Rizwan; Hairston John; Elsouda Dina,Astellas Pharma,None
31332693,Combination Treatment with an Antibody-Drug Conjugate (A1mcMMAF) Targeting the Oncofetal Glycoprotein 5T4 and Carboplatin Improves Survival in a Xenograft Model of Ovarian Cancer.,2019-08-01,Sapra Puja,Pfizer,Peter.Stern@cruk.manchester.ac.uk.
36828596,Contrived Materials and a Data Set for the Evaluation of Liquid Biopsy Tests: A Blood Profiling Atlas in Cancer (BLOODPAC) Community Study.,2023-03-01,Clement Omoshile; Corner Adam S; Jensen Jeffrey; Maar Dianna,SeraCare Life Sciences; Bio-Rad Laboratories,lauren@bloodpac.org.
34965947,The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial.,2022-03-01,Duggan William T,Pfizer,None
29507494,Real-world outcomes in patients with ALK-positive non-small cell lung cancer treated with crizotinib.,2018-02-01,Masters E T; Iyer S,Pfizer,None
39162127,Real-world prevalence of adverse events with first-line systemic therapies among patients with metastatic castration-sensitive prostate cancer.,2024-11-01,Xie Bin; Young Christopher; Ramaswamy Krishnan; El-Chaar Nader; Mucha Lisa,Astellas Pharma; Pfizer,None
34621011,Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial.,2022-02-01,Duggan William; Sugg Jennifer; Haas Gabriel P,Pfizer; Astellas,david.penson@vumc.org.
33506318,Does Biosimilar Bevacizumab Offer Affordable Treatment Options for Cancer Patients in the USA? A Budget Impact Analysis from US Commercial and Medicare Payer Perspectives.,2021-07-01,Yang Jingyan; Shelbaya Ahmed,Pfizer,jingyan.yang@pfizer.com.
34937730,Reversing T-cell Exhaustion in Cancer: Lessons Learned from PD-1/PD-L1 Immune Checkpoint Blockade.,2022-02-01,Budimir Natalija; Thomas Graham D; Dolina Joseph S; Salek-Ardakani Shahram,Pfizer,ssalekardakani@gmail.com
30962720,"A systematic review of international guidelines and recommendations for the genetic screening, diagnosis, genetic counseling, and treatment of <i>BRCA</i>-mutated breast cancer.",2019-01-01,Forbes Carol; Fayter Debra; de Kock Shelley; Quek Ruben Gw,Kleijnen Systematic Reviews; Pfizer,carol@systematic-reviews.com.
37531024,Healthcare Costs in Men with Metastatic Castration-Resistant Prostate Cancer: An Analysis of US Medicare Fee-For-Service Claims.,2023-10-01,Davis Matthew R; Epstein Andrew J; Ivanova Jasmina I,Medicus Economics; Pfizer,Stephen.Freedland@cshs.org.
39475418,Real-world effectiveness of palbociclib plus endocrine therapy in HR+/HER2- advanced breast cancer: final results from the POLARIS trial.,2024-10-30,Gauthier Eric; Zhang Zhe; Wang Yao,Pfizer,None
29222530,Seizure Rates in Enzalutamide-Treated Men With Metastatic Castration-Resistant Prostate Cancer and Risk of Seizure: The UPWARD Study.,2018-05-01,Krivoshik Andrew; Park Jung Wook,Astellas,None
37958441,Palbociclib Combined with an Aromatase Inhibitor in Patients with Breast Cancer with Lung or Liver Metastases in US Clinical Practice.,2023-11-02,Liu Xianchen; Li Benjamin; McRoy Lynn; Chen Connie,Pfizer,None
34234466,Demographic Characteristics and Treatment Patterns Among Patients Receiving Palbociclib for HR+/HER2- Advanced Breast Cancer: A Nationwide Real-World Experience.,2021-01-01,Rokszin György; Abonyi-Tóth Zsolt; Földesi Csenge,RxTarget; Pfizer,None
33612825,Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate.,2021-12-01,Ramaswamy Krishnan; Mardekian Jack; Schultz Neil M; Lechpammer Stanislav,Pfizer; Astellas Pharma,krishnan.ramaswamy@pfizer.com.
37585665,Plain language summary: Can declines in prostate-specific antigen level indicate how long patients with advanced prostate cancer will live when treated with enzalutamide?,2023-09-01,Lin Xun; Sugg Jennifer; Steinberg Joyce,Pfizer; Astellas Pharma,None
30189880,Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients.,2018-09-06,Rodriguez-Martínez Alba; Ilyine Hugh,DestiNA Genomics,mjose.serrano@genyo.es.
34848822,Correction: Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial.,2022-09-01,Duggan William; Sugg Jennifer; Haas Gabriel P,Pfizer; Astellas,david.penson@vumc.org.
30794760,"Real-world misuse, abuse, and dependence of abuse-deterrent versus non-abuse-deterrent extended-release morphine in Medicaid non-cancer patients.",2019-04-01,Mendoza Mario; Cattaneo Michael; Mardekian Jack; Park Peter W,b Centrexion; Pfizer,None
32162822,Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial.,2020-03-01,Chakrabarti Jayeta; Elmeliegy Mohamed; Gauthier Eric; Czibere Akos; Tudor Iulia Cristina; Quek Ruben G W,Pfizer,None
38536033,Treatment outcomes in older patients with metastatic breast cancer receiving palbociclib plus an aromatase inhibitor: a plain language summary.,2024-01-01,Liu Xianchen; McRoy Lynn; Chen Connie,Pfizer,None
30728048,Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy.,2019-02-06,Ilyine Hugh,DestiNA Genomics,mjose.serrano@genyo.es.
19209887,LC-MS/MS mediated absolute quantification and comparison of bile salt export pump and breast cancer resistance protein in livers and hepatocytes across species.,2009-03-15,Li Na,Department of,None
32159882,Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer.,2020-05-01,Tsuji Fumito,SFJ,None
31583515,Correction to: Combination Treatment with an Antibody-Drug Conjugate (A1mcMMAF) Targeting the Oncofetal Glycoprotein 5T4 and Carboplatin Improves Survival in a Xenograft Model of Ovarian Cancer.,2019-12-01,Sapra Puja,Pfizer,Peter.Stern@cruk.manchester.ac.uk.
36789668,The Role of Physician Specialty in the Underutilization of Standard-of-Care Treatment Intensification in Patients With Metastatic Castration-sensitive Prostate Cancer.,2023-06-01,Hong Agnes; El-Chaar Nader N; Nimke David,Pfizer; Astellas Pharma,None
39645562,Talazoparib plus enzalutamide versus olaparib plus abiraterone acetate and niraparib plus abiraterone acetate for metastatic castration-resistant prostate cancer: a matching-adjusted indirect comparison.,2024-12-07,Nazari Jonathan; Niyazov Alexander,Pfizer,ecastro.imas12@h12o.es.
37783836,Real-world treatment patterns and overall survival among men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) in the US Medicare population.,2024-06-01,Davis Matthew; Epstein Andrew J; Ivanova Jasmina I,Medicus Economics; Pfizer,Jasmina.Ivanova@pfizer.com.
11377037,LC/MS/MS quantitation of an anti-cancer drug in human plasma using a solid-phase extraction workstation: application to population pharmacokinetics.,2001-06-01,Penn L D,Department of,lara.penn@pfizer.com
28368708,Design and Rationale of the Metastatic Renal Cell Carcinoma (MaRCC) Registry: A Prospective Academic and Community-Based Study of Patients With Metastatic Renal Cell Cancer.,2017-05-28,Abernethy Amy P; Simantov Ronit; Borham Azah,b Pfizer,None
37882449,TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer.,2024-03-01,Chakrabarti Jayeta; Chen Hsiang-Chun; Niyazov Alexander,Pfizer,None
25944621,A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer.,2015-06-10,Gomez-Navarro Jesus; Yver Antoine; Dry Jonathan R; Galbraith Susan; Lehnert Manfred; Mortlock Andrew,Takeda; AstraZeneca,None
32959703,Indirect analysis of first-line therapy for advanced non-small-cell lung cancer with activating mutations in a Japanese population.,2021-01-01,Scory Tayler; Farris Megan S; Larkin-Kaiser Kelly A,Medlior Health Outcomes Research,None
34108262,International Consensus on Minimum Preclinical Testing Requirements for the Development of Innovative Therapies For Children and Adolescents with Cancer.,2021-08-01,Shields David J,Pfizer,gilles.vassal@gustaveroussy.fr.
36952230,"Characteristics, Treatment, and Outcomes of Real-World Talazoparib-Treated Patients With Germline BRCA-Mutated Advanced HER2-Negative Breast Cancer.",2023-05-08,Ivanova Jasmina; Niyazov Alexander; Ryan Joanne C,Pfizer,None
35840724,Correction: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate.,2022-04-01,Ramaswamy Krishnan; Mardekian Jack; Schultz Neil M; Lechpammer Stanislav,Pfizer; Astellas Pharma,krishnan.ramaswamy@pfizer.com.
33356529,Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses.,2021-05-01,Rosbrook Brad; Lee Ho-Jin; Haas Gabriel P,Pfizer; Astellas Pharma,None
25544584,The Impact of Molecularly Targeted Treatment on Direct Medical Costs in Patients with Advanced Non-small Cell Lung Cancer.,2015-04-01,Kim Young-Joo,Pfizer Pharmaceuticals Korea,None
25395283,"Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer.",2015-03-01,Benner R J; Green S; Molpus K,Pfizer,giorgio.scagliotti@unito.it.
39072356,"VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer.",2024-01-01,Lu Dongrui R; Liu Yuan,Pfizer,None
34854733,Health care resource utilization and costs associated with advanced or metastatic nonsmall cell lung cancer in the United States.,2022-02-01,Beachler Daniel C; Dinh Jade; Jamal-Allial Aziza,HealthCore,None
38995237,Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer.,2024-01-01,Lin Xun; Di Santo Nicola; Zohren Fabian,Pfizer; Formerly of Pfizer,None
39254990,A systematic review of health-related quality of life outcomes in patients with advanced breast cancer treated with palbociclib.,2024-10-01,Chen Connie; Cappelleri Joseph C; Makari Doris; Arruda Lillian Shahied; Hanson Kent; Doan Justin,Pfizer,None
20832981,Methylnaltrexone in the treatment of opioid-induced constipation in cancer patients receiving palliative care: willingness-to-pay and cost-benefit analysis.,2011-01-01,Iskedjian Michael; Wang Mike; Farah Bechara; Berbari Jade,PharmIdeas Research and Consulting; Pfizer Canada,None
30656571,"Clinical Outcomes, Treatment Patterns, and Health Resource Utilization Among Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutation: A Real-World Retrospective Study.",2019-03-01,Quek Ruben G W; Mardekian Jack,Pfizer,ruben.quek@pfizer.com.
37060432,A Phase I Clinical Trial Evaluating the Safety and Dosing of Relugolix with Novel Hormonal Therapy for the Treatment of Advanced Prostate Cancer.,2023-05-01,Gervasi Lawrence; Lu Sophia; Gatoulis Sergio C; Brown Bruce; Migoya Elizabeth,SouthWest Urology; Myovant Sciences; Pfizer,Jose.DeLaCerda@urologysa.com.
35767124,Comparative Analysis of All-Cause Health Care Resource Utilization and Costs Among Venous Thrombosis Patients Without Cancer Prescribed Apixaban or VKAs in France.,2022-08-01,Mokgokong Ruth,Pfizer,Ruth.mokgokong@pfizer.com.
35039606,Correction to: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate.,2022-04-01,Ramaswamy Krishnan; Mardekian Jack; Schultz Neil M; Lechpammer Stanislav,Pfizer; Astellas Pharma,krishnan.ramaswamy@pfizer.com.
39802535,A Real-World Evidence Primer for Advanced Practice Providers: Integrating P-Reality X Into Shared Decision-Making for People With HR+/HER2- Metastatic Breast Cancer.,2024-07-22,Ryan Joanne C,Pfizer,None
28578656,Treatment patterns and real world clinical outcomes in ER+/HER2- post-menopausal metastatic breast cancer patients in the United States.,2017-06-02,Zanotti Giovanni; Perkins Julia J; Horblyuk Ruslan,Pfizer,mhunger@mapigroup.com.
37179240,The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES.,2023-08-01,Rosbrook Brad; Zohren Fabian; Haas Gabriel P; Gourgiotti Georgia; El-Chaar Nader,Pfizer; Astellas Pharma,andrew.armstrong@duke.edu.
39589223,Systematic literature review and meta-analysis of health state utility values in metastatic castration-resistant prostate cancer.,2024-11-26,Nazari Jonathan; Niyazov Alexander,Pfizer,None
33171521,"Effectiveness and Safety of Apixaban, Low-Molecular-Weight Heparin, and Warfarin among Venous Thromboembolism Patients with Active Cancer: A U.S. Claims Data Analysis.",2021-03-01,Keshishian Allison; Lee Theodore; Hlavacek Patrick; Mardekian Jack; Wiederkehr Daniel; Sah Janvi; Luo Xuemei,SIMR; Pfizer,None
28857713,Low-molecular-weight heparins for the prevention of recurrent venous thromboembolism in patients with cancer: A systematic literature review of efficacy and cost-effectiveness.,2019-01-01,Dranitsaris George; Shane Lesley G; Woodruff Seth,Augmentium Pharma Consulting; Pfizer,None
33626934,Matching-adjusted indirect comparison of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive/HER2-negative advanced breast cancer.,2021-04-01,Zhan Lin; Bananis Eustratios; Mitra Debanjali,Pfizer,None
28827103,Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration Resistant Prostate Cancer in the TERRAIN Trial.,2018-01-01,Baron Benoit; van Os Steve; Hasabou Nahla; Wang Fong; Lin Ping,Astellas; Medivation,siemensr@kgh.kari.net.
33663223,CDK4/6 inhibitors in HR+/HER2- advanced/metastatic breast cancer: a systematic literature review of real-world evidence studies.,2021-06-01,Bartlett Meaghan; Spurden Dean; Hooper Becky; Zhan Lin; Rosta Emily; Cameron Chris; Mitra Debanjali; Zhou Anna,CRG-EVERSANA Canada; Pfizer,None
37831416,"Real-world treatment patterns for palbociclib plus an aromatase inhibitor, or an aromatase inhibitor alone, for patients with metastatic breast cancer in the Flatiron Database.",2024-02-15,Liu Xianchen; Li Benjamin; McRoy Lynn; Chen Connie,Pfizer,None
33955599,Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study.,2021-07-01,Rosbrook Brad; Sugg Jennifer; Baron Benoit; Chen Lucy; Kunieda Futoshi,Pfizer; Astellas Pharma,None
34813053,Worldwide Prevalence of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-Analysis.,2022-01-01,Bennetts Margherita; Nickens Dana J; Brinkmann Julia; Kayser Antonin; Moran Michael,Pfizer R&D UK; Pfizer; Pfizer Pharma; AbbVie Deutschland,BMelosky@bccancer.bc.ca.
33973232,Lorlatinib Exposure-Response Analyses for Safety and Efficacy in a Phase I/II Trial to Support Benefit-Risk Assessment in Non-Small Cell Lung Cancer.,2021-11-01,Chen Joseph; Ruiz-Garcia Ana; James Leonard P; Peltz Gerson; Thurm Holger; Clancy Jill; Hibma Jennifer,Pfizer,None
35227895,"Proteogenomic Analysis of Breast Cancer Transcriptomic and Proteomic Data, Using De Novo Transcript Assembly: Genome-Wide Identification of Novel Peptides and Clinical Implications.",2022-04-01,Tiwary Shivani,Pfizer Pharma,nameeta.shah@gmail.com.
29608887,Prediction of Human Brain Penetration of P-glycoprotein and Breast Cancer Resistance Protein Substrates Using In Vitro Transporter Studies and Animal Models.,2018-08-01,Feng Bo; Doran Angela C; Di Li; West Mark A; Osgood Sarah M; Mancuso Jessica Y; Shaffer Christopher L; Tremaine Larry; Liras Jennifer,Pfizer,bo.feng2@pfizer.com.
34585621,Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancer.,2021-12-01,Thurm Holger; Peltz Gerson,Pfizer,None
34346236,Real-world treatment patterns and outcomes in PD-L1-positive non-small cell lung cancer.,2021-12-01,Yang Mo; Masters Elizabeth T,EMD Serono; Pfizer,None
40129925,Real-world effectiveness of CDK4/6i in first-line treatment of HR+/HER2- advanced/metastatic breast cancer: updated systematic review.,2025-01-01,Rose Chloe Grace; Korytowsky Beata; Chen Connie,Pfizer,None
32112280,Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.,2020-05-01,Ramaswamy Krishnan; Lechpammer Stanislav; Mardekian Jack; Schultz Neil M; Sandin Rickard,Pfizer; Astellas,krishnan.ramaswamy@pfizer.com.
16596290,"GSTM1 and GSTT1 polymorphisms, cigarette smoking, and risk of colon cancer: a population-based case-control study in North Carolina (United States).",2006-05-01,Huang Kui,Pfizer,kui.a.huang@pfizer.com
25647781,"Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized Phase III trial.",2015-05-01,Fujii Yosuke; Kamei Yoichi; Takahashi Satori; Namazu Katsushi; Umeyama Yoshiko,Pfizer Japan,ioka-ta@mc.pref.osaka.jp.
31217344,Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2- Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial.,2019-12-01,Lu Dongrui R; Gauthier Eric; Schnell Patrick,Pfizer,v.dieras@rennes.unicancer.fr.
35643841,"Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER.",2022-07-01,Lin Ping; Duggan William; Sugg Jennifer; Russell David,Formerly of Pfizer; Pfizer; Astellas,anthony.joshua@svha.org.au.
37557181,"Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer.",2023-10-19,Ren Bin; Dennis Matthew L; Dolezal Olan; Nuttall Stewart; Peat Thomas S,Cancer,shikhar.sharma@pfizer.com.
35675470,"The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups.",2022-09-01,Rosbrook Brad; Ramaswamy Krishnan; Ganguli Arijit; Haas Gabriel P,Pfizer; Astellas Pharma,None
34595671,Modeling Challenges in Cost-Effectiveness Analysis of First-Line Immuno-Oncology Therapies in Non-small Cell Lung Cancer: A Systematic Literature Review.,2022-02-01,Masters Elizabeth,Pfizer,xinke.zhang@emdserono.com.
31858327,"Evaluation of the potential effect of dacomitinib, an EGFR tyrosine kinase inhibitor, on ECG parameters in patients with advanced non-small cell lung cancer.",2020-06-01,Tan Weiwei; Giri Nagdeep; Quinn Susan; Wilner Keith; Parivar Kourosh,Pfizer,weiwei.tan@pfizer.com.
30189902,Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials.,2018-09-06,Schultz Neil M; Yang Hongbo; Brown Bruce A; Barlev Arie; Flanders Scott C,Astellas; Analysis Group; Medivation; Pfizer,neil.schultz@astellas.com.
35122924,Increase in ADAR1p110 activates the canonical Wnt signaling pathway associated with aggressive phenotype in triple negative breast cancer cells.,2022-04-20,Lobos-González Lorena; Guevara Francisca,n Ciencia & Vida - Andes,rarmisen@udd.cl.
37296971,Low Molecular Weight Heparin Treatment Patterns and Outcomes in Cancer Patients with Acute Venous Thromboembolism: A Nationwide Cohort Study in France.,2023-05-31,Mokgokong Ruth,Pfizer,None
31329516,"ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.",2019-11-10,Sugg Jennifer; Baron Benoit; Chen Lucy,Astellas,None
35947814,"The Critical Role of Academic Clinical Trials in Pediatric Cancer Drug Approvals: Design, Conduct, and Fit for Purpose Data for Positive Regulatory Decisions.",2022-10-10,Barry Elly; Kieran Mark,Day One Biopharmaceuticals,None
35848218,Incidence of safety events after immune checkpoint inhibitor initiation for advanced-stage non-small-cell lung cancer: a real-world study.,2022-08-01,Beachler Daniel C; Dinh Jade; Papazian Anahit; Jamal-Allial Aziza,HealthCore,None
37343145,A Randomized Placebo-Controlled Trial of the Anti-Nerve Growth Factor Antibody Tanezumab in Subjects With Cancer Pain Due to Bone Metastasis.,2023-12-11,Dragon Erika; Brown Mark T; West Christine R; Bao Weihang; Agyemang Alex,Pfizer,None
40180682,Safety and Tolerability of Relugolix in Combination with Abiraterone or Apalutamide for Treatment of Patients with Advanced Prostate Cancer: Data from a 52-Week Clinical Trial.,2025-04-04,Gervasi Lawrence; Ryan Michael; Zhong Yi; Ufer Mike,SouthWest Urology; Pfizer; Sumitomo Pharma America; Sumitomo Pharma Switzerland,Jose.DeLaCerda@urologysa.com.
35619639,"Cancer-associated venous thromboembolism in Israel: Incidence, risk factors, treatment, and health care utilization in a population based cohort study.",2022-05-01,Friedman-Mazursky Orr; Tirosh Matanya,Medical Affairs Pfizer,None
30202945,Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer.,2018-11-01,Phung D; Krivoshik A,Astellas,andrew.armstrong@duke.edu.
26109878,"5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus sunitinib or bevacizumab as first-line treatment for metastatic colorectal cancer: a randomized Phase IIb study.",2015-01-01,Chow Maneval Edna,Seragon,None
28488142,A prospective randomized controlled trial of hydrating nail solution for prevention or treatment of onycholysis in breast cancer patients who received neoadjuvant/adjuvant docetaxel chemotherapy.,2017-08-01,Lee Soo-Hyeon,Pfizer,yhparkhmo@skku.edu.
39295563,Industry Perspective on First-in-Human and Clinical Pharmacology Strategies to Support Clinical Development of T-Cell Engaging Bispecific Antibodies for Cancer Therapy.,2025-01-01,Lechmann Martin; Wang Jun; Boetsch Christophe,Roche; Boehringer Ingelheim,None
29720233,Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced/metastatic breast cancer treated in community oncology practice in the USA one year post approval.,2018-05-02,Ward M A; Ahmed H V; McRoy L; Zanotti G,Pfizer,meleaward@icloud.com.
36842915,Survival and Economic Impact of Rapid Prostate-Specific Antigen Doubling Time in Patients With Nonmetastatic Castration-Resistant Prostate Cancer.,2023-08-01,Schultz Neil M,Astellas,stephen.freedland@cshs.org.
36358816,"<i>BRCA1/2</i> Mutation Testing in Patients with HER2-Negative Advanced Breast Cancer: Real-World Data from the United States, Europe, and Israel.",2022-11-02,Niyazov Alexander,Pfizer,None
37605861,Effectiveness of crizotinib in patients with <i>ROS1</i>-positive non-small-cell lung cancer: real-world evidence in Japan.,2023-12-01,Emir Birol; Wiltshire Robin,Pfizer,None
34618197,Phase I/II study to assess the clinical pharmacology and safety of single ascending and multiple subcutaneous doses of PF-06881894 in women with non-distantly metastatic breast cancer.,2021-12-01,Ottery Faith D,Ottery & Associates,hsuan-ming.yao@pfizer.com.
28689250,"Multicenter, cross-sectional observational study of the impact of neuropathic pain on quality of life in cancer patients.",2017-12-01,Kim Hyun Joo,Pfizer Pharmaceutical Korea,shinsw@kumc.or.kr.
30285696,Correction to: Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials.,2018-10-01,Schultz Neil M; Yang Hongbo; Brown Bruce A; Barlev Arie; Flanders Scott C,Astellas; Analysis Group; Medivation; Pfizer,neil.schultz@astellas.com.
39289919,Frequency of weight and body composition increases in advanced non-small cell lung cancer patients during first line therapy.,2024-12-01,Tzameli Iphigenia; Cobain Sonia; Collins Susie; Breen Danna M; Calle Roberto A,Pfizer; Pfizer R&D UK,None
35232230,Effectiveness of crizotinib versus entrectinib in <i>ROS1</i>-positive non-small-cell lung cancer using clinical and real-world data.,2022-06-01,Tremblay Gabriel; Groff Michael; Iadeluca Laura; Daniele Patrick; Wilner Keith; Wiltshire Robin; Bartolome Lauren; Usari Tiziana; Cappelleri Joseph C,Cytel; Pfizer,None
38997691,"A retrospective cohort study to evaluate disease burden, health care resource utilization, and costs in patients with breast cancer in Dubai, UAE.",2024-07-12,Zayed Mwa; Tahoun N; Ali A,Pfizer,bcramachandrachar@ae.imshealth.com.
38049622,First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial.,2024-01-01,Lin Xun; Di Santo Nicola; Laird A Douglas; Zohren Fabian,Pfizer,karim.fizazi@gustaveroussy.fr.
35714477,Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.,2022-06-01,Ganguli A; Bhadauria H; Oh M,Astellas Pharma,bertrand.tombal@uclouvain.be.
38509647,Genomic testing and targeted therapy of non-small cell lung cancer in China: a nationwide survey of physicians and clinical pathologists.,2024-03-01,Meng Xiao; Wu Meiling; Qian Cui,Department of Medical Affairs Pfizer Investment,None
28844372,Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe.,2018-07-01,Melhem-Bertrandt Amal; Baron Benoit,Astellas,johann.de-bono@icr.ac.uk.
35961201,Tumor-infiltrating neutrophils and peripheral neutrophil-to-lymphocyte ratio conversely predicted the prognosis of patients with non-small cell lung cancer.,2022-09-01,Wang Xiaoqi,Pfizer Investment Com,xiuwenwang12@sdu.edu.cn.
31298572,Systematic review and network meta-analysis of first-line therapy for advanced <i>EGFR</i>-positive non-small-cell lung cancer.,2019-08-01,Franek Jacob; Larkin-Kaiser Kelly A,Medlior Health Outcomes Research,None
37968169,"Optimizing outcomes for high-risk, non-muscle-invasive bladder cancer: The evolving role of PD-(L)1 inhibition.",2023-12-01,Brinkmann Julia; Blake-Haskins John A; Cesari Rossano,Pfizer Pharma; Pfizer,bedke@live.com.
37841423,Real-world treatment patterns and effectiveness of palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer aged 75 years or older.,2023-01-01,Liu Xianchen; Li Benjamin; McRoy Lynn; Chen Connie,Pfizer,None
34784577,Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region.,2021-12-01,Steinberg Joyce; Sugg Jennifer; Lin Xun; Shen Qi,Astellas; Pfizer,ugo.degiorgi@irst.emr.it.
33010985,Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring.,2020-12-01,Modelska Katharina; Lin Xun; Sugg Jennifer; Steinberg Joyce,Pfizer; Astellas,fred.saad@umontreal.ca.
37646326,Plain language summary: Does the amount of time it takes for prostate-specific antigen to double affect how long men with nonmetastatic castration-resistant prostate cancer live and their healthcare costs?,2023-10-01,Ramaswamy Krishnan; Schultz Neil M,Pfizer; Astellas Pharma,None
40016055,Effects of Enzalutamide on the Sexual Activity of Patients with Biochemically Recurrent Prostate Cancer: A Post Hoc Analysis of Patient-reported Outcomes in the EMBARK Study.,2025-02-26,Ivanova Jasmina I; Nasr Anchen F; Reisman Arlene L; Ganguli Arijit; Kral Pavol; Turnbull James,Pfizer; Astellas Pharma; IQVIA,nshore@auclinics.com.
30191463,"Treatment Duration, Healthcare Resource Utilization, and Costs Among Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate: A Retrospective Claims Analysis.",2018-10-01,Schultz Neil M; Flanders Scott C; Wilson Samuel; Brown Bruce A; Song Yan; Yang Hongbo; Lechpammer Stanislav,Astellas Pharma; Analysis Group; Pfizer,neil.schultz@astellas.com.
28752187,Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer.,2017-11-01,Wilson Florence R; Varu Abhishek; Mitra Debanjali; Cameron Chris; Iyer Shrividya,Cornerstone Research Group; Pfizer,ccameron@cornerstone-research.com.
33835229,"Pharmacokinetics, safety, activity, and biomarker analysis of palbociclib plus letrozole as first-line treatment for ER+/HER2- advanced breast cancer in Chinese women.",2021-07-01,Huang Yaling; Linn Carlos; Zhao Huadong,Pfizer,Xubinghe@medmail.com.cn.
34884981,The Impact of Enzalutamide on the Prostate Cancer Patient Experience: A Summary Review of Health-Related Quality of Life across Pivotal Clinical Trials.,2021-11-23,Ganguli Arijit,Astellas,None
38162494,The prognostic value of Eastern Cooperative Oncology Group performance status on overall survival among patients with metastatic prostate cancer: a systematic review and meta-analysis.,2023-01-01,Assayag Jonathan; Kim Chai; Chu Haitao; Webster Jennifer,Pfizer,None
32725539,Retrospective Observational Study of ALK-Inhibitor Therapy Sequencing and Outcomes in Patients with ALK-Positive Non-small Cell Lung Cancer.,2020-12-01,Chioda Marc D; Mardekian Jack; Masters Elizabeth T,Pfizer,david.waterhouse@usoncology.com.
39754979,Comparative overall survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2- metastatic breast cancer in the US real-world setting.,2025-01-01,Liu X; Li B; McRoy L; Estevez M,Pfizer; Flatiron Health,hope.rugo@ucsf.edu.
39486165,"Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study.",2024-12-01,Lin Xun; Di Santo Nicola,Pfizer; Formerly of Pfizer,Arun.Azad@petermac.org.
34120312,Evaluation of the Effect of Proton Pump Inhibitors on the Efficacy of Dacomitinib and Gefitinib in Patients with Advanced Non-Small Cell Lung Cancer and EGFR-Activating Mutations.,2021-12-01,Nickens Dana,Pfizer,Weiwei.tan@pfizer.com.
31830211,Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials.,2020-02-01,Sugg Jennifer,Astellas Pharma,None
38072761,Clinical Outcomes of Enzalutamide in Metastatic Hormone-sensitive Prostate Cancer in Patients Aged <75 and ≥75 Years: ARCHES Post Hoc Analysis.,2024-08-01,Rosbrook Brad; Zohren Fabian; Ma Jie; Haas Gabriel P,Pfizer; Astellas Pharma,fgveiga@telefonica.net.
40140551,Enzalutamide in patients with high-risk biochemically recurrent prostate cancer according to the European Association of Urology definition: a post hoc analysis of EMBARK.,2025-03-26,Tarazi Jamal; Tang Yiyun; Haas Gabriel P; Rosales Matt,Pfizer; Astellas Pharma,nshore@auclinics.com.
33591468,The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer.,2021-05-01,Steinberg Joyce; Sugg Jennifer; Tudor Iulia C,Astellas Pharma; Pfizer,ian_krop@dfci.harvard.edu.
28236776,Evolving landscape of human epidermal growth factor receptor 2-positive breast cancer treatment and the future of biosimilars.,2017-04-01,Jacobs Ira,Pfizer,christian.jackisch@sana.de.
31854456,Comparing the effectiveness of different EGFR-TKIs in patients with EGFR mutant non-small-cell lung cancer: A retrospective cohort study in Taiwan.,2020-08-15,Fang Wei-Tse; Lo Yu-Wen,Pfizer,None
38297094,Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial.,2024-05-01,Lin Xun; Di Santo Nicola; Laird A Douglas; Zohren Fabian,Pfizer,karim.fizazi@gustaveroussy.fr.
29522174,Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical Trial.,2018-05-01,Bhattacharya Suman; Phung De; Krivoshik Andrew,Medivation; Astellas,None
32988969,A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast Cancer.,2020-12-01,Steinberg Joyce; Markova Denka; Tarazi Jamal; Zhu Zhou; O'Brien Thomas,Astellas; Formerly of Pfizer; Pfizer,ikrop@partners.org.
35950899,Plain language summary of the design of the TALAPRO-2 study comparing talazoparib and enzalutamide versus enzalutamide and placebo in men with metastatic castration-resistant prostate cancer.,2022-09-01,Paccagnella Maria Luisa; Santo Nicola Di; Elmeliegy Mohamed; Lin Xun; Czibere Akos,Pfizer,None
35750582,Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1.,2023-04-01,Dorff Tanya,Department of Medical Oncology &,fred.saad@umontreal.ca.
29351570,Joint adolescent-adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform-ACCELERATE.,2018-03-01,Rousseau R; Kerloeguen Y; Taube T; Uttenreuther-Fischer M,Gritstone Oncology; Hoffmann-La Roche; Pharma,nathalie.gaspar@gustaveroussy.fr.
33428292,Outcomes in patients with lung cancer treated with crizotinib and erlotinib in routine clinical practice: A post-authorization safety cohort study conducted in Europe and in the United States.,2021-06-01,Huang Kui; Mo Jingping; Schachterle Stephen E; Wilner Keith D,Pfizer,None
31274110,Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial.,2019-11-01,Lin Ping; Phung De; Parli Teresa; Krivoshik Andrew,Pfizer; Astellas; Astellas Pharma,andrew.armstrong@duke.edu.
30523750,Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.,2019-01-20,Koehler Maria,Bicycle,None
35200588,Real-World Treatment Patterns and Clinical Effectiveness of Palbociclib Plus an Aromatase Inhibitor as First-Line Therapy in Advanced/Metastatic Breast Cancer: Analysis from the US Syapse Learning Health Network.,2022-02-12,Mitra Debanjali; Alfred Tamuno; Emir Birol; Liu Xianchen; DiCristo Caroline; Chen Connie,Pfizer,None
31557987,"Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer.",2016-03-04,Root Adam R; Cao Wei; Li Bilian; LaPan Peter; Meade Caryl; Sanford Jocelyn; Jin Macy; O'Sullivan Cliona; Cummins Emma; Lambert Matthew; Sheehan Alfredo D; Ma Weijun; Gatto Scott; Kerns Kelvin; Lam Khetemenee; D'Antona Aaron M; Zhu Lily; Brady William A; Benard Susan; King Amy; He Tao; Racie Lisa; Arai Maya; Barrett Dianah; Stochaj Wayne; LaVallie Edward R; Apgar James R; Svenson Kristine; Mosyak Lidia; Finlay William J J; Lin Laura; Olland Stéphane; Somers William; Gerber Hans-Peter; May Chad; Tchistiakova Lioudmila; Bloom Laird,Pfizer,adam.root@pfizer.com.
29505670,Clinical and economic burden associated with stage III to IV triple-negative breast cancer: A SEER-Medicare historical cohort study in elderly women in the United States.,2018-05-15,Schultz Neil M; Flanders Scott C,Astellas Pharma,None
37173513,Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden.,2023-07-01,Iadeluca Laura,Pfizer,Fredrik.Nilsson@pfizer.com.
32527692,Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial.,2020-09-01,Lin Ping; Rosbrook Brad; van Os Steve,Pfizer; Astellas,andrew.armstrong@duke.edu.
32828825,Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.,2020-11-01,Quek R G W; Czibere A,Pfizer,jlitton@mdanderson.org.
31313942,Effects of dose modifications on the safety and efficacy of dacomitinib for <i>EGFR</i> mutation-positive non-small-cell lung cancer.,2019-08-01,Linke Rolf,SFJ,None
39581892,Real-world quality-of-life of patients with HR+/HER2- advanced breast cancer treated with palbociclib plus endocrine therapy: EORTC QLQ-C30 results from POLARIS.,2025-02-01,Migas John,Oncology Associates,grocque@uabmc.edu.
35046678,Treatment Outcomes of High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) in Real-World Evidence (RWE) Studies: Systematic Literature Review (SLR).,2022-01-01,Musat Mihaela Georgiana; Kwon Christina Soeun; Forsythe Anna,a Wholly Owned Subsidiary of Cytel,None
34419726,"Population-based recurrence rates among older women with HR-positive, HER2-negative early breast cancer: Clinical risk factors, frailty status, and differences by race.",2021-10-01,Cueto Jenilee; Mitra Debanjali; Law Ernest H,Pfizer,gcalip@uic.edu.
32869649,Network meta analysis of first-line therapy for advanced EGFR mutation positive non-small-cell lung cancer: updated overall survival.,2020-12-01,Farris MeganS; Larkin-Kaiser Kelly A; Scory Tayler,Medlior Health Outcomes Research,None
38869771,"Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status.",2024-09-01,Yuan Yuan; Mata Marielena; Laird A Douglas,Department of Medical Oncology &; Pfizer,mtelli@stanford.edu.
36849516,Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial.,2023-02-27,Collins Barbara,Simbiotic Consulting,vpapadimitrakopoulou@gmail.com.
39786430,Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1-Pretreated Metastatic Non-Small Cell Lung Cancer and Metastatic Cutaneous Melanoma.,2025-03-03,Chaney Marya; Lu Hailing; Berndt Jason; O'Connor Brian P; Rathi Kapil; Shaikh Eeman,Pfizer,None
33937954,Pharmacokinetics of Lorlatinib After Single and Multiple Dosing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: Results from a Global Phase I/II Study.,2021-10-01,O'Gorman Melissa T,Pfizer,Joseph.Chen@pfizer.com.
39868402,Occurrence and management of thrombosis recurrence and bleeding in low-molecular-weight heparin-treated patients with cancer-associated thrombosis: a French nationwide cohort study.,2025-01-01,Mokgokong Ruth,Pfizer,None
21700731,"Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy.",2012-03-01,Munster P N,Departments of Breast and Experimental,m-campone@nantes.fnclcc.fr.
37318349,"Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study.",2023-10-03,Yuan Yuan; Niyazov Alexander; Chakrabarti Jayeta; Czibere Akos,Department of Medical Oncology &; Pfizer,None
38650388,Mortality burden of pre-treatment weight loss in patients with non-small-cell lung cancer: A systematic literature review and meta-analysis.,2024-08-01,Smoyer Karen E,Envision,None
33584653,"Proceedings From the First International Workshop at Sidra Medicine: ""Engineered Immune Cells in Cancer Immunotherapy (EICCI): From Discovery to Off-the-Shelf Development"", 15<sup>th</sup>-16<sup>th</sup> February 2019, Doha, Qatar.",2020-01-01,Brentjens Renier; Buchholz Christian J; van der Vliet Hans J,Cellular; Research Unit for Molecular; Lava,None
38817906,"Clinical characteristics, treatment patterns, and outcomes in adult patients with germline <i>BRCA1/2</i>-mutated, HER2-negative advanced breast cancer: a retrospective medical record review in the United States.",2024-01-01,Arruda Lillian Shahied; Niyazov Alexander,Pfizer,None
34080140,The Cost-Effectiveness of Lorlatinib Versus Chemotherapy as a Second- or Third-Line Treatment in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small-cell Lung Cancer in Sweden.,2021-08-01,Masters Elizabeth T; Iadeluca Laura,Pfizer,Fredrik.Nilsson@pfizer.com.
28786423,Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes.,2018-05-22,Warren L; Williams L S; Jackson N; Byrne J,Teva; Novartis; Adaptimmune,None
30502785,Important Group Differences on the Functional Assessment of Cancer Therapy-Kidney Symptom Index Disease-Related Symptoms in Patients with Metastatic Renal Cell Carcinoma.,2018-12-01,Cappelleri Joseph C; Ramaswamy Krishnan; Hariharan Subramanian; Bushmakin Andrew G,Pfizer,d-cella@northwestern.edu.
36124924,"Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses.",2022-10-01,Dorff Tanya; Chen Hsiang-Chun; Di Santo Nicola,Medical Oncology &; Pfizer,None
32653773,Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma.,2020-09-01,Buckland Sean; Caron Hubert,Pfizer; Hoffmann-La Roche,lucas.moreno@vhebron.net.
34207794,Vitamin D Supplementation Regulates Postoperative Serum Levels of PD-L1 in Patients with Digestive Tract Cancer and Improves Survivals in the Highest Quintile of PD-L1: A Post Hoc Analysis of the AMATERASU Randomized Controlled Trial.,2021-06-09,Morita Makoto,Pfizer Japan,None
28270497,"NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer.",2017-08-01,Bartlett Cynthia Huang; Koehler Maria,Pfizer,cynthiaxma@wustl.edu
30770294,"Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial.",2019-04-01,Morlock Robert,Astellas Pharma,bertrand.tombal@uclouvain.be.
35133617,"Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study.",2022-01-01,Tajima Kentaro,Pfizer Japan,Rubikli@yahoo.com.
33634624,Palbociclib Plus Fulvestrant in Korean Patients from PALOMA-3 With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.,2021-02-01,Bananis Eustratios; Huang Xin,Pfizer,moisa@snu.ac.kr.
30124753,Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial.,2018-09-01,Quek R G W; Markova D; Bhattacharyya H; Hannah A L,Pfizer,johannes.ettl@tum.de.
35131133,Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial.,2022-03-01,Lockhart Stephen P; Hariharan Subramanian; Kitchin Nicholas; Bailey Ruth; Liau Katherine; Koury Kenneth; Dychter Samuel S; Lu Claire; Gruber William C,Pfizer,ThomStep@upstate.edu.
36517634,Prostate-specific antigen response and clinical progression-free survival in Black and White men with chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide in a real-world setting.,2023-09-01,Hong Agnes; El-Chaar Nader; Ramaswamy Krishnan; Nimke David,Astellas Pharma; Pfizer,stephen.freedland@cshs.org.
39360943,Efficacy in patients with <i>EGFR</i>-positive non-small-cell lung cancer treated with dacomitinib who had skin adverse events: <i>post hoc</i> analyses from ARCHER 1050.,2024-01-01,Linke Rolf,SFJ Pharmaceuticals,None
40139460,Final Survival Results from the Penelope-B trial investigating palbociclib vs placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after neoadjuvant chemotherapy - PENELOPE-B.,2025-03-24,Loibl S; Zhang Z; Hirmas N; Holtschmidt J; Nekljudova V,Forschungs; Pfizer,sibylle.loibl@gbg.de.
39348626,Registry of Genetic Alterations of Taiwan Non-Small Cell Lung Cancer by Comprehensive Next-Generation Sequencing: A Real-World Cohort Study-Taiwan Cooperative Oncology Group T1521.,2024-09-01,Ku Fan-Chen; Fang Wei-Tse,Co; Pfizer,None
30359909,Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial.,2018-11-01,Quek R G W; Bhattacharyya H; Hannah A L,Pfizer,SHurvitz@mednet.ucla.edu.
27029704,"Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial.",2016-06-01,Loibl S,German Breast Group Forschungs,nadia.harbeck@med.uni-muenchen.de.
35429901,"Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study.",2022-06-01,Corsaro Massimo; Huang Xin,Pfizer,mmartin@geicam.org.
39368244,Systematic review and network meta-analysis of lorlatinib with comparison to other anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) as first-line treatment for ALK-positive advanced non-smallcell lung cancer (NSCLC).,2024-11-01,Polli Anna; Thomaidou Despina; Le Hannah,Pfizer,Hannah.Le@pfizer.com.
35846244,"Health-related Quality of Life in Hormone Receptor-Positive Early Breast Cancer: Analyses From the Surveillance, Epidemiology, and End Results Medicare Health Outcomes Survey.",2022-01-01,Cueto Jenilee; Mitra Debanjali; Law Ernest H,Pfizer,None
30839234,Management of common adverse events related to first-line dacomitinib use in <i>EGFR</i> mutation-positive non-small-cell lung cancer: a pooled safety analysis.,2019-05-01,Wang Tao; Sandin Rickard; Noonan Kay; Gernhardt Diana,Pfizer,None
19225039,"The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice.",2009-05-01,Zhou Lin,Pfizer,None
31065873,"Surrogate threshold effect based on a meta-analysis for the predictive value of progression-free survival for overall survival in hormone receptor-positive, HER2-negative metastatic breast cancer.",2019-08-01,Böhme Sarah; Hücherig Stephanie; Jeratsch Ulli; Kürschner Niclas,Pfizer Deutschland; AMS Advanced Medical Services,m.lux@vincenz.de.
34385241,A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design.,2021-08-12,Sugg Jennifer; Haas Gabriel P,Astellas,stephen.freedland@cshs.org.
32472430,Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.,2020-07-01,Mardekian Jack; Wiltshire Robin; Togo Kanae,Pfizer; Pfizer Japan,ygoto-tky@umin.net.
25456362,"Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial.",2014-12-01,Zhang Hui,Research & Development Co,pasi_janne@dfci.harvard.edu.
33331989,Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.,2021-02-01,Chawla Alka; Noonan Kay,SFJ; Pfizer,syylwu@live.cn.
38749072,Efficacy and safety of crizotinib in the treatment of advanced non-small cell lung cancer with ROS1 gene fusion: a systematic literature review and meta-analysis of real-world evidence.,2024-06-01,Rifi Nada; Le Hannah,Pfizer,esnadal@iconcologia.net.
39947094,Brain metastases and mortality in patients with ALK + metastatic non-small cell lung cancer treated with second-generation ALK tyrosine kinase inhibitors as first-line targeted therapies: An observational cohort study.,2025-03-01,Marcum Zachary A; Davis Matthew,Medicus Economics,upretyd@karmanos.org.
20231298,A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease.,2010-09-01,Zhang X; Cisar L,Pfizer,zatloukp@fnb.cz.
34756500,"Corrigendum to 'Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)' [European Journal of Cancer 152 (2021) 116-128].",2022-01-01,Gollerkeri Ashwin,Pfizer,helgogas@gmail.com.
35660971,Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial.,2022-07-01,Hooi Wong Chew,Pfizer Pte,ross_soo@nuhs.edu.sg.
26894413,Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment.,2016-05-01,Bell T; Bhattacharyya H; Zanotti G; Randolph S; Kim S; Huang X; Huang Bartlett C,a Pfizer; d Pfizer,None
37441939,Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.,2023-09-01,Gounaris Ioannis; Unger T J,Merck Serono; Repare,andy1pearson@btinternet.com.
32336645,"Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study.",2020-10-01,Morlock Robert; Ramaswamy Krishnan,Astellas Pharma; Pfizer,arnulf.stenzl@med.uni-tuebingen.de.
27368881,"Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3).",2016-10-01,Schnell Patrick; Zhang Ke; Thiele Alexandra,Pfizer,DrSunil.Verma@ahs.ca.
29209525,Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer.,2017-01-01,Reisman Arlene,Pfizer Global Innovative,None
28958502,"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.",2017-11-01,Tsuji Fumito; Linke Rolf,SFJ,syylwu@live.cn.
33385521,"Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL.",2021-04-01,Koehler M,Repare,mmartin@geicam.org.
33721611,"Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050).",2021-04-01,Linke Rolf; Wong Chew Hooi; Zhu Fanfan; Wilner Keith D,SFJ Pharmaceuticals; Pfizer,syylwu@live.cn.
28899363,A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer.,2017-09-12,Salgia Ravi; Seroutou Abdelkader; Tian Xianbin; Fernandez Rose; Morozov Alex; Ramkumar Thiruvamoor; Zubel Angela,Department of Medical Oncology and; Novartis; Pfizer,kreynolds7@partners.org.
33486783,Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-Up.,2021-05-01,Schnell Patrick; Lu Dongrui R; Gauthier Eric; Bananis Eustratios,Pfizer,None
24880774,"Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study.",2014-08-01,Mancini Pierre,Roche TCRC,Sophie.postel-vinay@gustaveroussy.fr.
38642245,Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study.,2024-07-01,Kosaka Nobuyoshi; Tajima Kentaro,Pfizer Japan,nmasuda@alpha.ocn.ne.jp.
